Physician

Scott James Samuelson, M.D.

According to 2025 Medicare claims, Scott Samuelson, M.D. (NPI: 1922288588) practices medical oncology in the Salt Lake City-Murray, UT market, with the plurality of this provider's patient population coming from Salt Lake, UT. This provider's primary affiliated billing organization is UTAH CANCER SPECIALISTS PC (NPI: 1619925369; TIN: 870519691) and primary practice location at 84102-2310.

Samuelson's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 278 traditional Medicare patients, billed 80,480 HCPCS/CPT codes, and received $1,767,517 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 904 prescription claims across 141 beneficiaries totaling $3,867,607 in drug costs, led by Cabometyx (Cabozantinib S-Malate). 2021 DME data shows 31 claims. Open Payments data shows 25 records totaling $530. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $1,821,772 and ending at $3,867,607. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	404	71,552	$1,233,788
2016	530	77,311	$1,861,839
2017	460	81,060	$1,814,638
2018	316	80,162	$2,383,901
2019	303	72,294	$1,897,009
2020	299	49,390	$1,846,878
2021	304	57,830	$1,723,835
2022	321	68,221	$1,908,064
2023	322	64,943	$1,548,701
2024	278	80,480	$1,767,517

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	148	949	$1,821,772
2016	174	915	$2,587,959
2017	161	864	$2,944,705
2018	153	1,024	$4,112,559
2019	156	975	$3,432,185
2020	145	866	$3,392,369
2021	131	869	$4,971,540
2022	155	1,001	$5,371,852
2023	143	829	$2,899,524
2024	141	904	$3,867,607

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	51	$8,856
2016	N/R	55	$7,287
2017	N/R	14	$6,436
2018	N/R	66	$8,186
2019	N/R	N/R	N/R
2020	N/R	77	$11,864
2021	N/R	31	$3,621
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	124	381	$91
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	138	258	$62
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	87	179	$12
80053	Blood test, comprehensive group of blood chemicals	193	732	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	203	816	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Cabometyx	Cabozantinib S-Malate	24	720	$585,550
Imbruvica	Ibrutinib	37	1,038	$549,714
Revlimid	Lenalidomide	17	476	$415,024
Xtandi	Enzalutamide	28	840	$341,998
Ibrance	Palbociclib	20	560	$306,753

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	23	$530	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	2	$7,071	Cornerstone Specialty Network LLC

Explore More Providers

FAQ

What Medicare data is available for Scott James Samuelson, M.D.?

Tedicare shows public-source Medicare data for Scott James Samuelson, M.D. (NPI 1922288588), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Scott James Samuelson, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Scott James Samuelson, M.D.?

Scott James Samuelson, M.D. is linked to UTAH CANCER SPECIALISTS PC (billing NPI 1619925369) in the available physician profile data.

Does Scott James Samuelson, M.D. have Open Payments data?

Scott James Samuelson, M.D. has 25 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.